Analyst Price Target is $7.40
▲ +432.37% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Actinium Pharmaceuticals in the last 3 months. The average price target is $7.40, with a high forecast of $21.00 and a low forecast of $2.00. The average price target represents a 432.37% upside from the last price of $1.39.
Current Consensus is
Moderate Buy
The current consensus among 5 investment analysts is to moderate buy stock in Actinium Pharmaceuticals. This rating has held steady since July 2024, when it changed from a Buy consensus rating.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
Read More
